Skip to main content
This product has additional discounts available which will be visible once you checkout.
Digital Recordings

The Use of Mind-Altering Substances: MDMA, Psilocybin, and Marijuana for Treating PTSD and Other Mental Distress


Average Rating:
Not yet rated
Speakers:
Michael Mithoefer, MD |  Ismail Ali |  Brian Richards, PsyD |  Gita Vaid, MD |  Rachel Yehuda, PhD |  Rick Doblin, PhD |  Anne Wagner, PhD, C Psych |  James W. Hopper, PhD |  Elizabeth Call, PsyD |  Susan Walker, MD |  Francis Guerriero, MA, LICSW |  Michael Alpert, MD |   1 more....
Duration:
3 Hours 49 Minutes
Copyright:
May 19, 2022
Product Code:
POS058918
Media Type:
Digital Recordings


Description

For the first time in over four decades, researchers are returning to examining the therapeutic benefits of mind altering substances, including MDMA (ecstasy), psilocybin (mushrooms), marijuana and LSD. In the 1970s the study of all psychedelics was criminalized in the US, despite emerging evidence of their medical value. Over the past decade, the Multidisciplinary Association for Psychedelic Research (MAPS) has helped to revive psychedelic research, sponsoring studies across the United States and around the world, including MDMA-assisted therapy for PTSD, and end-of-life anxiety. The results have been very positive, lasting over 72 months of follow-up, with few adverse effects. Psychedelics may promote a deepening and acceleration of the psychotherapeutic process. During therapy, people often are able to access and find peace with disavowed, "exiled" parts of themselves. In this recording, the Principal Investigator of the Phase I and II level trials will discuss outcomes and processes.

CPD


CPD

This online program is worth 4 hours CPD.



Handouts

Speaker

Michael Mithoefer, MD's Profile

Michael Mithoefer, MD Related seminars and products


Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.

 

Speaker Disclosures:

Financial: Dr. Michael Mithoefer has employment relationships with the Medical University of South Carolina and the Multidisciplinary Association for Psychedelic Studies. He has an ownership interest in Awakn Life Sciences and serves on the scientific advisory board. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.

Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.

 


Ismail Ali's Profile

Ismail Ali Related seminars and products


Ismail Lourido Ali, JD, is Director of Policy and Advocacy for the Multidisciplinary Association for Psychedelic Studies (MAPS), a founding board member of the Psychedelic Bar Association, and former Chair of the Board of Directors for Students for Sensible Drug Policy.

 

Speaker Disclosures:
Financial: Ismail Ali is the policy and advocacy director for Multidisciplinary Association for Psychedelic Studies. He receives a speaking honorarium from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Ismail Ali works as an activist for compassionate drug policies. He is the founding board member of the Psychedelic Bar Association.


Brian Richards, PsyD's Profile

Brian Richards, PsyD Related seminars and products


Brian D. Richards, PsyD, completed a master’s degree in Existential-Phenomenological Psychology at Duquesne University, a PsyD at the University of Denver School for Professional Psychology, and a Postdoctoral Fellowship at the Johns Hopkins Behavioral Pharmacology Research Unit, where he contributed to some of the original research administering psilocybin with cancer patients and healthy normal adults. Dr. Richards was formerly a Clinical Director with MedOptions, the largest behavioral health provider in the United States. He also provides Advanced Screenings at Oasis, an acute outpatient center in Maryland, and cares for patients with a cancer diagnosis at Maryland oncology Hematology, The Aquilino Cancer Center. Dr. Richards was a Lead Trainer and Mentor for Compass Pathways (a UK-based Life Sciences Company), and he also mentors students at the California Institute for Integral Studies, the leading Psychedelic Medicine Certificate Program worldwide.
 

Speaker Disclosures:
Financial: Dr. Brian Richards has employment relationships with the Center for Psychedelic Therapies and Research, Maryland Oncology Hematology, Sunstone Medical, Johns Hopkins University School of Medicine, and the Oasis the Center for Mental Health. He receives a speaking honorarium from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Brian Richards has no relevant non-financial relationships.


Gita Vaid, MD's Profile

Gita Vaid, MD Related seminars and products


Gita Vaid, MD, is a board-certified psychiatrist and psychoanalyst and co-founder of the Center for Natural Intelligence, a multidisciplinary laboratory dedicated to psychedelic psychotherapy innovation and clinical practice. A lead instructor at The Ketamine Training Center and a member of the Mount Sinai Psychedelic Psychotherapy Research and Trauma Center, she is a Multidisciplinary Association for Psychedelic Studies-trained psychedelic psychotherapist practicing ketamine-assisted psychotherapy in New York City. Vaid completed her residency training at NYU Medical Center and psychoanalytic training at the Psychoanalytic Association of New York. She trained as a fellow in clinical psychopharmacology and neurophysiology at New York Medical College and completed a research fellowship at NYU Medical Center.


Speaker Disclosures:
Financial: Gita Vaid maintains a private practice. She has an employment relationship with The Ketamine Training Center Faculty. Gita Vaid receives a speaking honorarium from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Gita Vaid is a member of the American Psychiatric Association.


Rachel Yehuda, PhD's Profile

Rachel Yehuda, PhD Related seminars and products


Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience, is the Director of the Center for Psychedelic Psychotherapy and Trauma Research. She is also Director of the Traumatic Stress Studies Division at the Mount Sinai School of Medicine, which includes the PTSD clinical research program and the Neurochemistry and Neuroendocrinology laboratory the James J. Peters Veterans Affairs Medical Center. Dr. Yehuda is a recognized leader in the field of traumatic stress studies.

She has authored more than 450 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD. Her current interests include the study of risk and resilience factors, psychological and biological predictors of treatment response in PTSD, genetic and epigenetic studies of PTSD and the intergenerational transmission of trauma an PTSD. She has an active federally-funded clinical and research program that welcomes local and international students and clinicians.


Speaker Disclosures:
Financial: Dr. Rachel Yehuda has an employment relationship with the Icahn School of Medicine at Mount Sinai and the Department of Veterans Affairs. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Rachel Yehuda is a member of the International Society for Traumatic Stress Studies, the International Society for Neuroscience, and the Anxiety Disorder Association of America. She serves on the scientific advisory board for the National Anxiety Foundation. Dr. Yehuda is an ad hoc grant reviewer for the VA Merit Review Committee, the Department of Defense (DOD), and the National Institute of Mental Health (NIMH).


Rick Doblin, PhD's Profile

Rick Doblin, PhD Related seminars and products


Rick Doblin, PhD, Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS); chair of the board of directors MAPS Public Benefit Corporation.

 

Speaker Disclosures:
Financial: Richard Doblin has an employment relationship with Multidisciplinary Association for Psychedelic Studies, Inc. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Richard Doblin has no relevant non-financial relationships.


Anne Wagner, PhD, C Psych's Profile

Anne Wagner, PhD, C Psych Related seminars and products


Anne Wagner, PhD, CPsych, Adjunct Professor, Department of Psychology & Associate Member, Yeates School of Graduate Studies at Ryerson University, Toronto. Trainer in CBCT and CPT. Team member, MDMA trial for Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD. Founder of Remedy (www.remedycentre.ca), a centre for mental health innovation.

Speaker Disclosures:
Financial: Anne Wagner is the founder of Remedy and Remedy Institute. She has an employment relationship with Ryerson University. Anne Wagner receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Anne Wagner is a member of the Canadian Psychological Association, the International Society of Traumatic Stress Studies, and Association for Behavioral and Cognitive Therapies. She is an Ad hoc reviewer and editor for several peer review journals, for a complete list contact PESI, Inc.


James W. Hopper, PhD's Profile

James W. Hopper, PhD Related seminars and products


James W. Hopper, PhD, Independent consultant and Instructor in Psychology, Cambridge Health Alliance & Harvard Medical School.  Co-editor, Mindfulness-Oriented Interventions for Trauma: Integrating Contemplative Practices.  The MDMA Team, Trauma Research Foundation.

Speaker Disclosures:
Financial: Dr. James Hopper maintains a private practice and has employment relationships with Harvard Medical School and Cambridge Health Alliance. He is a sub-investigator and therapist for Phase 2 & 3 MDMA-assisted psychotherapy research, with MAPS/MPBC and The Trauma Research Foundation. Dr. Hopper receives royalties as a published author. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. James Hopper is a member of the International Society for Traumatic Stress Studies.


Elizabeth Call, PsyD's Profile

Elizabeth Call, PsyD Related seminars and products


Elizabeth Call, PsyD, Psychologist in private practice. Therapy team member, MDMA study, the Trauma Research Foundation.

 

Speaker Disclosures:
Financial: Dr. Elizabeth Call maintains a private practice and has an employment relationship with the EMDR Institute. She receives a consulting fee from the Multidisciplinary Association for Psychedelic Studies (MAPS). Dr. Call is a sub-investigator for FDA phase III trials of MDMA-assisted psychotherapy sponsored by MAPS/MPBC and The Trauma Research Foundation. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Elizabeth Call is a member of the EMDR International Association.


Susan Walker, MD's Profile

Susan Walker, MD Related seminars and products


Susan Walker, MD, Instructor in Psychiatry, Harvard Medical School. Child and Adolescent Psychiatrist, Cambridge health Alliance. MDMA Therapy Team Member, the Trauma Research Foundation. Co-principal Investigator, Boston Site of MAPS sponsored MDMA for PTSD study.

Speaker Disclosures:
Financial: Susan Walker is a clinical sub-investigator and therapist with MAPS/MPBC and The Trauma Research Foundation. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Susan Walker is a member of the American Psychiatric Association and American Psychiatric Association.


Francis Guerriero, MA, LICSW's Profile

Francis Guerriero, MA, LICSW Related seminars and products


Francis Guerriero, MA, LICSW, Private practice, Cambridge, MA; MDMA Therapy team member, The Trauma Research Foundation.


Speaker Disclosures:
Financial: Francis Guerriero maintains a private practice and has an employment relationship with the Trauma Research Foundation. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Francis Guerriero has a professional relationship as a therapist and sub-investigator under Multidisciplinary Association for Psychedelic Studies (MAPS).


Michael Alpert, MD's Profile

Michael Alpert, MD Related seminars and products


Michael D. Alpert, MD, Staff Psychiatrist, BayCove Mental Health Center, Boston Harvard Medical School; MDMA Therapy team member, the Trauma Research Foundation.

Speaker Disclosures:
Financial: Dr. Michael Alpert maintains a private practice. He has employment relationships with Cambridge Health Alliance, Harvard Medical School, and Trauma Research Foundation. Dr. Alpert receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Michael Alpert is a member of the American Psychiatric Association.


Bessel van der Kolk, MD's Profile

Bessel van der Kolk, MD Related seminars and products


Bessel A. van der Kolk, MD, is a clinician, researcher and teacher in the area of post-traumatic stress. His work integrates developmental, neurobiological, psychodynamic and interpersonal aspects of the impact of trauma and its treatment.

Dr. van der Kolk and his various collaborators have published extensively on the impact of trauma on development, such as dissociative problems, borderline personality and self-mutilation, cognitive development, memory, and the psychobiology of trauma. He has published over 150 peer-reviewed scientific articles on such diverse topics as neuroimaging, self-injury, memory, neurofeedback, Developmental Trauma, yoga, theater, and EMDR. 

He is founder of the Trauma Center in Brookline, Massachusetts and President of the Trauma Research Foundation, which promotes clinical, scientific, and educational projects. 

His 2014 #1 New York Times best seller, The Body Keeps the Score: Brain, Mind, and Body in the Treatment of Trauma, transforms our understanding of traumatic stress, revealing how it literally rearranges the brain’s wiring – specifically areas dedicated to pleasure, engagement, control, and trust. He shows how these areas can be reactivated through innovative treatments including neurofeedback, somatically based therapies, EMDR, psychodrama, play, yoga, and other therapies.

Dr. van der Kolk is the past president of the International Society for Traumatic Stress Studies, and professor of psychiatry at Boston University Medical School. He regularly teaches at conferences, universities, and hospitals around the world.

 

Speaker Disclosures:
Financial: Dr. Bessel van der Kolk is a professor at Boston University School of Medicine, the Director of the Trauma Center, and the National Complex Trauma Network. He receives royalties as a published author. Dr. van der Kolk receives a speaking honorarium, recording royalties, and book royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Bessel van der Kolk has no relevant non-financial relationships.


Additional Info

Program Information

Access for Self-Study (Non-Interactive)

Access never expires for this product.

For a more detailed outline that includes times or durations of time, if needed, please email cepesi@pesi.com


Questions?

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info


Objectives

  1. Evaluate the emerging research of MDMA-Assisted Psychotherapy (MDMA-AP) and describe effective ways of integrating it into ongoing psychotherapy to improve clinical outcomes for clients with PTSD.
  2. Analyze the history and contemporary research of Psilocybin and evaluate the effectiveness of Psilocybin-Assisted Psychotherapy (PAP) in facilitating psychotherapy.
  3. Assess the ongoing work with marijuana and LSD.
  4. Formulate methods of integration of psychedelic-assisted therapy in contemporary treatment for mental illness.
  5. Determine key areas of investigation regarding therapeutic potentials of classic 5-HT2A agonist psychedelics for mental healthcare.

Outline

  • The utility of combining pre-existing treatments with MDMA-assisted psychotherapy
    • CPT
    • CBCT
  • Evolve the treatment model so as to enhance efficacy and efficiency
  • Understanding the complexity of treating patients with a cancer diagnosis
  • Specific case studies to highlight experience and outcomes
  • The Transformational Process
    • What features defines such a process?
  • The use of the therapeutic relationship
  • Expanded states of consciousness

Target Audience

  • Addiction Counselors
  • Counselors
  • Therapists
  • Psychotherapists
  • Marriage & Family Therapists
  • Nurses
  • Physicians
  • Psychologists
  • Social Workers
  • Other Mental Health Professionals

Reviews

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesi.co.uk or call 01235847393.

Please wait ...

Back to Top